CTSO Cytosorbents Corp

Price (delayed)

$1.8

Market cap

$78.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$59.68M

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the ...

Highlights
The quick ratio is down by 47% YoY but it is up by 4.5% QoQ
The equity has declined by 36% year-on-year and by 14% since the previous quarter
The gross profit has declined by 23% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of CTSO
Market
Shares outstanding
43.58M
Market cap
$78.44M
Enterprise value
$59.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.65
Price to sales (P/S)
2.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.58
Earnings
Revenue
$37.73M
EBIT
-$36.35M
EBITDA
-$34.93M
Free cash flow
-$33.44M
Per share
EPS
-$0.83
Free cash flow per share
-$0.77
Book value per share
$1.09
Revenue per share
$0.87
TBVPS
$1.63
Balance sheet
Total assets
$71.21M
Total liabilities
$23.65M
Debt
$13.09M
Equity
$47.56M
Working capital
$31.09M
Liquidity
Debt to equity
0.28
Current ratio
3.95
Quick ratio
3.51
Net debt/EBITDA
0.54
Margins
EBITDA margin
-92.6%
Gross margin
69.7%
Net margin
-94.2%
Operating margin
-82.5%
Efficiency
Return on assets
-41.9%
Return on equity
-60.2%
Return on invested capital
-96.6%
Return on capital employed
-59.9%
Return on sales
-96.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTSO stock price

How has the Cytosorbents stock price performed over time
Intraday
-1.64%
1 week
-7.69%
1 month
-19.28%
1 year
-75.9%
YTD
-57.04%
QTD
-17.81%

Financial performance

How have Cytosorbents's revenue and profit performed over time
Revenue
$37.73M
Gross profit
$26.32M
Operating income
-$31.12M
Net income
-$35.56M
Gross margin
69.7%
Net margin
-94.2%
CTSO's operating income has dropped by 152% year-on-year and by 12% since the previous quarter
The net margin has declined by 32% since the previous quarter
Cytosorbents's operating margin has decreased by 23% QoQ
The gross profit has declined by 23% year-on-year and by 14% since the previous quarter

Growth

What is Cytosorbents's growth rate over time

Valuation

What is Cytosorbents stock price valuation
P/E
N/A
P/B
1.65
P/S
2.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.58
CTSO's EPS is down by 20% from the previous quarter
CTSO's P/B is 87% lower than its 5-year quarterly average of 12.8 and 46% lower than its last 4 quarters average of 3.1
The equity has declined by 36% year-on-year and by 14% since the previous quarter
The stock's price to sales (P/S) is 78% less than its 5-year quarterly average of 9.4 and 53% less than its last 4 quarters average of 4.5
Cytosorbents's revenue has decreased by 16% YoY and by 9% QoQ

Efficiency

How efficient is Cytosorbents business performance
The ROIC has plunged by 52% YoY and by 15% from the previous quarter
The ROE has contracted by 35% from the previous quarter
CTSO's ROS is down by 32% from the previous quarter
The ROA has decreased by 31% QoQ

Dividends

What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTSO.

Financial health

How did Cytosorbents financials performed over time
The quick ratio is down by 47% YoY but it is up by 4.5% QoQ
CTSO's current ratio is down by 45% year-on-year but it is up by 3.7% since the previous quarter
The debt is 72% smaller than the equity
The debt to equity has soared by 65% year-on-year and by 17% since the previous quarter
The equity has declined by 36% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.